Nowen23andMe Holding Co. Unclaimed
South San Francisco, California, United States
Publicly traded personal genomics and biotechnology company offering direct-to-consumer genetic testing and ancestry-related health insights.
23andMe Holding Co. is a publicly held personal genomics and biotechnology company. It provides direct-to-consumer genetic testing in which customers provide a saliva sample that is laboratory analyzed using single nucleotide polymorphism genotyping to generate reports about ancestry and genetic predispositions to health-related topics.
To empower individuals with accessible genetic information about their ancestry and health through consumer genetics testing.
Market segments
Market size by segment
Growth potential (CAGR)
Direct-to-consumer ancestry and traits testing
Services that provide consumers with ancestry composition, ethnicity estimates, and trait reports derived from SNP genotyping of saliva samples.
Consumer genomic health and carrier screening
Non-diagnostic reports that inform individuals about genetic predispositions, carrier status, and common health-related risk markers for personal health awareness and family planning.
Data licensing and embedded datasets
APIs and licensed data products to embed private company data, predictive signals, and enrichment into customer products, models, and internal systems.
Research core facilities and genomics services
Shared research infrastructure and assay services including core billing, equipment reservation and management, and targeted gene expression assays (Nanostring) for translational research.
References
Methodology and sourcing behind the figures shown above.
Direct-to-consumer ancestry and traits testing
Estimates are based on published DTC genetic-testing market reports showing total market sizes in 2024–2026 and reported segment shares. GMInsights values the global DTC market at USD 4.1B (2024) and notes Ancestry held >25% share; other reports (Zion, Precedence, Vision/BioSpace) show 2024–2026 totals of roughly USD 1.95–2.45B. Assuming ancestry and trait SNP-genotyping (ancestry + traits) account for ~30–40% of the overall DTC market, applying a 35% share to GMInsights’ USD 4.1B yields ~USD 1.4B. Reported overall DTC CAGRs range ~12–24%; using a conservative midpoint for the ancestry/traits subsegment gives ~15% CAGR (reflecting mature ancestry demand but continued growth in trait/personalization offerings).
- The global direct-to-consumer (DTC) genetic testing market size was valued at USD 4.1 billion in 2024.
- Ancestry led with over 25% market share in 2024.
- the global direct-to-consumer (DTC) genetic testing market size was worth around USD 1.95 Billion in 2024 and projected to reach USD 17.43 Billion by 2034 (CAGR 24.5%).
- the global direct-to-consumer genetic testing market size was estimated at USD 2.17 billion in 2025 and predicted to increase from USD 2.45 billion in 2026 to approximately USD 11.02 billion by 2035 (CAGR 17.64%).
- Direct-to-consumer genetic testing market size is calculated at USD 2.43 billion in 2024; expected to be worth around USD 17.35 billion by 2033 (CAGR 24.43%).
Consumer genomic health and carrier screening
Primary estimate uses the Market Research Future carrier screening market figure (global carrier screening market = USD 6.105B in 2024) and its projected CAGR (8.82% for 2025–2035). Contextual DTC and broader genetic-testing reports (US DTC: USD 1.85B in 2023; global genetic testing: USD 24.45B in 2025 / USD 11.90B in 2024 by other sources) were reviewed to validate scope and growth direction.
- Carrier Screening Market Size was estimated at 6.105 USD Billion in 2024; CAGR 8.82% (2025 - 2035).
- United States Direct-to-Consumer Genetic Testing Market Size was valued at USD 1.85 Billion in 2023; CAGR 10.5% (2023-2033).
- Global genetic testing market size is USD 24.45 billion in 2025; CAGR 11.26% (2026-2035).
- Global genetic testing market valued at USD 11.90 billion in 2024; expected USD 91.30 billion by 2034; CAGR 22.6% (2024-2034).
Data licensing and embedded datasets
Used AI training-dataset market reports in the search results as a proximate market (MarketsandMarkets, Fortune Business Insights, Precedence Research). Those reports show 2024–2025 market sizes of roughly USD 2.8–3.6B and CAGRs of ~16–28%. Data licensing and embedded datasets (APIs, licensed feeds, dataset marketplaces) are a subset/adjacent segment of that market; based on the reported ranges and the segment’s overlap with dataset marketplaces and services, I estimate current market ≈ USD 3.0B and growth potential ≈ 24% CAGR.
- AI training dataset market size is estimated to be USD 2.82 billion in 2024 and is set to grow at a CAGR of 27.7%.
- The global AI training dataset market size was valued at USD 3.59 billion in 2025 and ... CAGR of 22.90% (2026–2034).
- The global AI training dataset market size accounted for USD 3.35 billion in 2025 ... CAGR (2026 - 2035) 16.13%.
Research core facilities and genomics services
Estimate uses published genomics services market reports as a proxy for the research core facilities and genomics services segment (core billing, equipment management, targeted assays). GMI Insights and SNSInsider report the genomics services market at roughly $8.5B (2024) and $7.94B (2025) respectively, with CAGR estimates ~11.5–11.8%. These service-focused figures are more directly relevant than broader ‘genomics’ market estimates that include instruments and products; therefore a market size ~USD 8.5B and CAGR ~11.5% are used.
Related Organizations
- CI
Crunchbase Inc.
Crunchbase is a global data and software platform that provides private company information and market insights.
about.crunchbase.com - TC
The University of Tennessee Health Science Center
Public health sciences university advancing education, research, clinical care, and public service.
www.uthsc.edu